Literature DB >> 21544080

Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers.

W Couet1, N Grégoire, P Gobin, P J Saulnier, D Frasca, S Marchand, O Mimoz.   

Abstract

Colistin pharmacokinetics (PK) was investigated in young healthy volunteers after a 1-h infusion of 80 mg (1 million international units (MIU)) of the prodrug colistin methanesulfonate (CMS). Concentration levels of CMS and colistin were determined in plasma and urine using a new chromatographic assay and analyzed simultaneously with a population approach after correcting the urine-related data for postexcretion hydrolysis of CMS into colistin. CMS and colistin have low volumes of distribution (14.0 and 12.4 liters, respectively), consistent with distribution being restricted to extracellular fluid. CMS is mainly excreted unchanged in urine (70% on average), with a typical renal clearance estimated at 103 ml/min-close to the glomerular filtration rate. Colistin elimination is essentially extrarenal, given that its renal clearance is 1.9 ml/min, consistent with extensive reabsorption. Colistin elimination is not limited by the formation rate because its half-life (3 h) is longer than that of CMS. The values of these pharmacokinetic parameters will serve as reference points for future comparisons with patients' data.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21544080     DOI: 10.1038/clpt.2011.48

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  42 in total

1.  Colistin distribution in the peritoneal fluid of a patient with severe peritonitis.

Authors:  Olivier Mimoz; Franck Petitpas; Nicolas Grégoire; Patrice Gobin; Sandrine Marchand; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2012-04-30       Impact factor: 5.191

2.  Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill.

Authors:  Ami F Mohamed; Ilias Karaiskos; Diamantis Plachouras; Matti Karvanen; Konstantinos Pontikis; Britt Jansson; Evangelos Papadomichelakis; Anastasia Antoniadou; Helen Giamarellou; Apostolos Armaganidis; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

3.  [Colistin : renaissance of an old antibiotic?].

Authors:  H Stocker; W V Kern
Journal:  Internist (Berl)       Date:  2013-08       Impact factor: 0.743

4.  Pharmacokinetics of four different brands of colistimethate and formed colistin in rats.

Authors:  Hui He; Ji-Chang Li; Roger L Nation; Jovan Jacob; Gong Chen; Hee Ji Lee; Brian T Tsuji; Philip E Thompson; Kade Roberts; Tony Velkov; Jian Li
Journal:  J Antimicrob Chemother       Date:  2013-06-07       Impact factor: 5.790

5.  Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis.

Authors:  Pornpan Koomanachai; Cornelia B Landersdorfer; Gong Chen; Hee Ji Lee; Anupop Jitmuang; Somkiat Wasuwattakul; Suchai Sritippayawan; Jian Li; Roger L Nation; Visanu Thamlikitkul
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

Review 6.  Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients.

Authors:  Mojdeh S Heavner; Kimberly C Claeys; Anne M Masich; Jeffrey P Gonzales
Journal:  Curr Infect Dis Rep       Date:  2018-04-05       Impact factor: 3.725

7.  Pharmacokinetics of Colistin Methansulphonate (CMS) and Colistin after CMS Nebulisation in Baboon Monkeys.

Authors:  Sandrine Marchand; Salim Bouchene; Michèle de Monte; Laurent Guilleminault; Jérôme Montharu; Maria Cabrera; Nicolas Grégoire; Patrice Gobin; Patrice Diot; William Couet; Laurent Vecellio
Journal:  Pharm Res       Date:  2015-06-04       Impact factor: 4.200

8.  In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.

Authors:  Kady Phe; Yuman Lee; Patrick M McDaneld; Nishant Prasad; Taijun Yin; Deborah A Figueroa; William L Musick; Jessica M Cottreau; Ming Hu; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

9.  Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.

Authors:  Cornelia B Landersdorfer; Tri-Hung Nguyen; Linh Thuy Lieu; Gary Nguyen; Robert J Bischof; Els N Meeusen; Jian Li; Roger L Nation; Michelle P McIntosh
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

Review 10.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.